Tralokinumab: Discovering the Promise of LP 0162 and CAT-354 Tralokinumab, previously known as LP 0162 and CAT-354, represents a novel approach for atopic dermatitis. This specific antibody inhibits IL-13, https://www.targetmol.com/compound/tralokinumab